$サイクラセル・ファーマシューティカルズ(CYCC.US)$Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(4.74) by 52.11 percent. This is a 67.8 percent increase over losses of $(7.05) per share from the same period last year. The company reported $29.00 thousand in sales this quarter.
サイクラセル・ファーマシューティカルズに関するコメント
まだコメントはありません